The story of the erectile dysfunction drug presents a complex picture for shareholders. While the initial introduction generated significant returns, the lapse of its patent opened the door to cheaper versions, https://wisesocialsmedia.com/story7162619/viagra-and-the-pharmaceutical-industry-a-risky-bet